Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer 公告 2024-12-17 16:50:31 Written By Kym Kilbourne Clinical Trial I: Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer ClinicalTrials.gov ID: NCT04931381 Sponsor: Changhai Hospital Provider of Information: Guo Shiwei, Changhai Hospital (Responsible Party) Last Update Posted: 2022-08-02 Study Overview Brief Summary The purpose of this study is to explore whether chemotherapy regimens guided by organoid drug sensitivity testing can improve the prognosis of advanced pancreatic cancer. Additionally, this study will assess the extraction of drugs from biopsy tissues by organoids and investigate the consistency between drug sensitivity test results and patient treatment responses. Detailed Description The poor prognosis of pancreatic cancer is not only due to the high malignancy of the tumor itself but also its poor response to chemotherapy. Currently, patient drug sensitivity is assessed by the progression time after treatment. Therefore, it is difficult to determine patient drug sensitivity before chemotherapy. Organoids are a new type of tumor model with the potential to test drug sensitivity before chemotherapy. Our center's previous experience has shown a success rate of 77.6% for pancreatic cancer organoid culture. Preliminary studies have confirmed that pancreatic cancer organoids are highly consistent with the original tissue in genomics and histomorphology. More importantly, researchers have tested the sensitivity of five first-line drugs in 39 pancreatic cancer organoids and compared the test results with the clinical treatment responses of these patients, confirming that organoids can accurately assess chemotherapy drug sensitivity. This is a single-center, prospective, open-label, randomized, controlled clinical trial aimed at exploring whether chemotherapy regimens guided by organoid drug sensitivity testing can improve the prognosis of patients with advanced pancreatic cancer. It will also analyze the consistency between drug sensitivity test results and patient treatment responses. Additionally, the radio sensitivity of organoids will be tested and compared with the patient's response to radiotherapy. Official Title A Prospective, Randomized, Controlled Trial of Chemotherapy for Advanced Pancreatic Cancer Based on Organoid Drug Sensitivity Testing Condition Advanced Pancreatic Cancer Intervention/Treatment Other: Chemotherapy guided by organoid drug sensitivity testing Other Study ID Numbers Changhai H-PP09 Contact and Location Information Study Contact Name: Guo Shiwei, MD Phone: +8618621500666 Email: gestwa@163.com Backup Study Contact Name: Wang Huanshi Phone: +8617317492841 Email: mr_wang_huan@163.com Study Link: https://clinicaltrials.gov/study/NCT04931381?term=organoid%20Guided&aggFilters=status:rec&rank=1 Kym Kilbourne
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer 公告 2024-12-17 16:50:31 Written By Kym Kilbourne Clinical Trial I: Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer ClinicalTrials.gov ID: NCT04931381 Sponsor: Changhai Hospital Provider of Information: Guo Shiwei, Changhai Hospital (Responsible Party) Last Update Posted: 2022-08-02 Study Overview Brief Summary The purpose of this study is to explore whether chemotherapy regimens guided by organoid drug sensitivity testing can improve the prognosis of advanced pancreatic cancer. Additionally, this study will assess the extraction of drugs from biopsy tissues by organoids and investigate the consistency between drug sensitivity test results and patient treatment responses. Detailed Description The poor prognosis of pancreatic cancer is not only due to the high malignancy of the tumor itself but also its poor response to chemotherapy. Currently, patient drug sensitivity is assessed by the progression time after treatment. Therefore, it is difficult to determine patient drug sensitivity before chemotherapy. Organoids are a new type of tumor model with the potential to test drug sensitivity before chemotherapy. Our center's previous experience has shown a success rate of 77.6% for pancreatic cancer organoid culture. Preliminary studies have confirmed that pancreatic cancer organoids are highly consistent with the original tissue in genomics and histomorphology. More importantly, researchers have tested the sensitivity of five first-line drugs in 39 pancreatic cancer organoids and compared the test results with the clinical treatment responses of these patients, confirming that organoids can accurately assess chemotherapy drug sensitivity. This is a single-center, prospective, open-label, randomized, controlled clinical trial aimed at exploring whether chemotherapy regimens guided by organoid drug sensitivity testing can improve the prognosis of patients with advanced pancreatic cancer. It will also analyze the consistency between drug sensitivity test results and patient treatment responses. Additionally, the radio sensitivity of organoids will be tested and compared with the patient's response to radiotherapy. Official Title A Prospective, Randomized, Controlled Trial of Chemotherapy for Advanced Pancreatic Cancer Based on Organoid Drug Sensitivity Testing Condition Advanced Pancreatic Cancer Intervention/Treatment Other: Chemotherapy guided by organoid drug sensitivity testing Other Study ID Numbers Changhai H-PP09 Contact and Location Information Study Contact Name: Guo Shiwei, MD Phone: +8618621500666 Email: gestwa@163.com Backup Study Contact Name: Wang Huanshi Phone: +8617317492841 Email: mr_wang_huan@163.com Study Link: https://clinicaltrials.gov/study/NCT04931381?term=organoid%20Guided&aggFilters=status:rec&rank=1 Kym Kilbourne
